Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Passage BioPASG -6.85%32 12-1 Month Momentum % is -36.83% as of Jul. 28, 2026. GuruFocus rates PASG with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,357 Biotechnology companies, Passage Bio ranks worse than 66.03% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-28), Passage Bio's 12-1 Month Momentum % is -36.83%.
The industry rank for Passage Bio's 12-1 Month Momentum % or its related term are showing as below:
PASG's 12-1 Month Momentum % is ranked worse than 66.03% of 1357
companies
in the Biotechnology industry
Industry Median: -20.24
vs PASG: -36.83
Passage Bio (NAS:PASG) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Passage Bio 12-1 Month Momentum % Related Terms
PASG vs OTLC, KTTA, LSTA: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Passage Bio's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Passage Bio 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Passage Bio's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Passage Bio's 12-1 Month Momentum % falls into.
Passage Bio (NAS:PASG) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -36.83% mean?
Passage Bio (PASG) has a 12-1 Month Momentum % of -36.83% as of Jul. 28, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Passage Bio and its competitors. According to the industry distribution chart, Passage Bio ranks #896 out of 1357 companies in the Biotechnology industry, placing it in the top 66%.
Is Passage Bio's 12-1 Month Momentum % too high?
Passage Bio's current 12-1 Month Momentum % is -36.83%. Based on the distribution chart, Passage Bio ranks #896 out of 1357 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Passage Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's 12-1 Month Momentum % compare to OTLC and KTTA?
According to the Biotechnology industry distribution chart, Passage Bio ranks #896 out of 1357 companies for 12-1 Month Momentum %. This places Passage Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Passage Bio and its competitors. Passage Bio's current 12-1 Month Momentum % is -36.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current 12-1 Month Momentum % of -36.83%. The current 12-1 Month Momentum % is -36.83%. Passage Bio's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Passage Bio (PASG), the current 12-1 Month Momentum % is -36.83% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
32GF Score
Get the complete analysis for PASG
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASG has been successfully added to your 
